NEW YORK (GenomeWeb) – British research tools maker Abcam announced today that it has signed an agreement to acquire Cambridge, Mass.-based Firefly BioWorks for £18.5 million ($28 million) in cash.

Founded in 2010, Firefly has developed a multiplex assay biomarker-detection platform based on a proprietary technology called optical liquid stamping, which combines photolithography with microfluidics. The company's first products allow for the detection of cellular and circulating microRNAs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.